Emerging role of safinamide in Parkinson’s disease therapy

European Neurological Review

Volumn 9, Issue 2, 2014, Pages 108-112

  Kulisevsky, Jaime ^a,b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT OBERTA DE CATALUNYA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Add on therapy; Dopaminergic; Dyskinesia; Monoamine oxidase b; Non dopaminergic; Parkinson s disease; Safinamide

Indexed keywords

EID: 84982728775     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2014.09.02.108     Document Type: Review

References (34)

1. Graybiel AM, Neurotransmitters and neuromodulators in the basal ganglia, Trends Neurosci, 1990;13,244–54.
2. Albin RL, Young AB, Penney JB, The functional anatomy of disorders of the basal ganglia, Trends Neurosci, 1995;18:63–4.
3. Braak H, Del Tredici K, Rub U, et al., Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol Aging, 2003;24:197–211.
4. Fox SH, Non-dopaminergic treatments for motor control in Parkinson’s disease, Drugs, 2013;73:1405–15.
5. Huot P, Fox SH, Nondopaminergic treatments for Parkinson’s disease, Neurodegener Dis Manag, 2011;1:491–512.
6. Blandini F, Porter RH, Greenamyre JT, Glutamate and Parkinson’s disease, Mol Neurobiol, 1996;12:73–94.
7. Chase TN, Bibbiani F, Oh JD, Striatal glutamatergic mechanisms and extrapyramidal movement disorders, Neurotox Res, 2003;5:139–46.
8. Borgohain R, Kandadai RM, Safinamide: a novel anti- Parkinsonian drug with multiple actions, Neurodegen Dis Manage 2013;3:231–40.
9. Pevarello P, Bonsignori A, Dostert P, et al., Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl) amino] alkanamide derivatives, J Med Chem, 1998;41:579–90.
10. Caccia C, Maj R, Calabresi M, et al., Safinamide: from molecular targets to a new anti-Parkinson drug, Neurology, 2006;67(7 Suppl. 2):S18–23.
11. Caccia C, Salvati P, Rossetti S, Anand R, Safinamide: Modulation of dopaminergic and glutamatergic system, Mov Disord, 2008;67:S22–3.
12. Chazot PL, Safinamide for the treatment of Parkinson’s disease, epilepsy and restless legs syndrome, Curr Opin Investig Drugs, 2007;8:570–9.
13. Binda C, Wang J, Pisani L, et al., Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs, J Med Chem, 2007;50:5848–52.
14. Onofrj M, Bonanni L, Thomas A, An expert opinion on safinamide in Parkinson’s disease, Expert Opin Investig Drugs, 2008;17:1115–25.
15. Muller T, Current status of safinamide for the drug portfolio of Parkinson’s disease therapy, Expert Rev Neurother, 2013;13:969–77.
16. Gregoire L, Jourdain VA, Townsend M, et al., Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys, Parkinsonism Relat Disord, 2013;19:508–14.
17. Fariello RG, McArthur RA, Bonsignori A, et al., Preclinical evaluation of PNU-151774E as a novel anticonvulsant, J Pharmacol Exp Ther, 1998;285:397–403.
18. Vaghi F, Maj R, Rosa B, et al., Neuroprotective effect of PNU- 151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils, Soc Neurosci Abstr, 1997;23:545.
19. Maj R, Fariello RG, Ukmar G, et al., PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat, Eur J Pharmacol, 1998;359:27–32.
20. Kupsch A, Sautter J, Gotz ME, et al., Monoamine oxidaseinhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline, J Neural Transm, 2001;108:985–1009.
21. Stocchi F, Borgohain R, Onofrj M, et al., A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients, Mov Disord, 2012;27:106–12.
22. Schapira AH, Stocchi F, Borgohain R, et al., Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease, Eur J Neurol, 2013;20:271–80.
23. Anand R, Barone P, Fox S, et al., Safinamide is effective as add-on treatment in both early and advanced PD. Presented at the XXI World Congress of Neurology, Wien, Austria, 21–26 September 2013.
24. Schapira AH, Fox S, Hauser, K., et al., Safinamide significantly improves responder rates in fluctuating PD patients as add-on to levodopa (SETTLE). Presented at the 17th International Congress of Parkinson’s Disease and Movement Disorders, Sydney, Australia, 16–20 June 2013.
25. Borgohain R, Szasz J, Stanzione P, et al., Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations, Mov Disord, 2014;29:229–37.
26. Borgohain R, Szasz J, Stanzione P, et al., Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late PD, Mov Disord, 2014;29:1273–80.
27. Marzo A, Dal Bo L, Monti NC, et al., Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity, Pharmacol Res, 2004;50:77–85.
28. Leuratti C, Sardina M, Ventura P, et al., Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers, Pharmacology, 2013;92:207–16.
29. Walker SE, Shulman KI, Tailor SA, Gardner D, Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets, J Clin Psychopharmacol, 1996;16:383–8.
30. Cattaneo C, Caccia C, Marzo A, et al., Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition, Clin Neuropharmacol, 2003;26:213–7.
31. Di Stefano AF, Rusca A, Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers, Naunyn Schmiedebergs Arch Pharmacol, 2011;384:505–15.
32. Stocchi F, Arnold G, Onofrj M, et al., Improvement of motor function in early Parkinson disease by safinamide, Neurology, 2004;63:746–8.
33. Goetz CG, Stebbins GT, Shale HM, et al., Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intrarater reliability assessment, Mov Disord, 1994;9:390–4.
34. Kalasz H, Magyar K, Szke E, et al., Metabolism of selegiline [(-)-deprenyl], Curr Med Chem, 2014;21(13):1522–30.